Browse Articles
Discover research articles across all indexed journals
Comparative evaluation of manual and automated ACMG/AMP variant classification: implications for clinical genetic practice
Abstract Automated implementations of the ACMG/AMP variant classification guidelines are increasingly used to support clinical genomics, yet systematic comparisons with expert human curation remain limited. In this study, we benchmarked several widely used automated and AI‑assisted tools, including Franklin, VarSome, MobiDetails, GeneBe, InterVar, and VarChat, against dual independent curator assessments across diverse variant types. We quantified criterion‑level agreement, evidence weighting behavior, and classification concordance, with a particular focus on calibration around key ACMG criteria. Our analyses revealed that discrepancies between tools and curators concentrated around evidence‑strength calibration and near‑boundary categories (LP↔P, LP↔VUS). Loss‑of‑function variants showed the highest concordance, reflecting the maturity of PVS1‑based decision trees, whereas missense and splicing variants exhibited wider variability driven by differences in PM1 hotspot definitions, PP3/BP4 predictor thresholds, and access to case‑level and segregation evidence. Tool‑specific patterns were evident: Franklin and VarSome demonstrated high concordance but a slight pathogenic-leaning bias; VarChat showed near‑neutral calibration; GeneBe yielded higher and more variable evidence totals; and InterVar applied more conservative, lower‑weight scoring. Overall, our findings indicate that automated tools perform reliably for structured, data‑rich evidence but benefit from expert adjudication for context‑dependent criteria. This is especially relevant as laboratories prepare for the forthcoming ACMG v4 framework while still operating under established ACMG and ACGS recommendations, creating a transitional period in which robust and transparent workflows remain essential.
Photoregulated Structural Memory in Supramolecular Polymers
Experimental investigation on enhancing the geotechnical properties of sabkha soil using sodium silicate and waste glass powder to reduce collapsibility
Multicentered <i>p–s–p*</i> Antibonding Interaction Induces Strong Anharmonicity and High Thermoelectric Performance in Complex Metal Chalcohalide Tl <b> <sub>5</sub> </b> Te <b> <sub>2</sub> </b> I
High-sensitivity vitreous proteomic analyses reveal involvement of IL-10/JAK–STAT signaling in the proliferative changes of retinopathy of prematurity
Plasmonic Re-Excitation Enables Superoxide-Mediated Ethane Conversion to Acetic Acid under Visible Light
Graded oxygenation levels and clinical outcomes among patients with traumatic brain injury: a propensity score-matched multicenter analysis
Triple Pancake Bonding in Neutral π-Conjugated Dimers: a Computational Study
Effect of post-weaning glutamine and/or liquid milk replacer supplementation on pig growth and intestinal development
Growth-Coupled Assembly of Hydrogen-Bonded Organic Framework Membranes on Cell Surfaces
Real-world effectiveness and clinical predictors of response to first-generation TTR silencers in variant ATTR amyloidosis with polyneuropathy
Abstract Transthyretin (TTR) gene-silencing therapies have transformed the management of variant transthyretin amyloidosis with polyneuropathy (ATTRv-PN). However, real-world evidence on effectiveness, safety and durability is limited. We conducted a multicenter retrospective study across ten Spanish referral hospitals including 98 genetically confirmed ATTRv-PN amyloidosis patients treated with patisiran (n = 81) or inotersen (n = 17). Patients were classified as total, partial, or non-responders according to clinical evolution and Neuropathy Impairment Score (NIS). Baseline clinical, neurophysiological (CMAP, SNAP, ESC), and biochemical parameters were analyzed. Longitudinal NIS changes, treatment persistence, and safety were assessed. Total responders had higher baseline CMAP amplitudes (p = 0.045), while baseline neurophysiological measures showed modest discriminatory capacity overall, with electrochemical skin conductance providing the strongest signal. Baseline renal function differed across groups (eGFR, p = 0.022), but the direction of this association was not consistent with improved response. Compared with inotersen, patisiran showed a higher total response rate (59.3% vs. 23.5%), slower NIS progression (median + 0.31 vs. +4.00 points/year; p = 0.011), and greater treatment persistence (log-rank p = 0.0005). No discontinuations due to adverse events occurred with patisiran, versus 41.2% with inotersen. ESC showed the highest predictive value (AUC 0.681 overall; 0.783 in the patisiran subgroup), while baseline NIS was less informative. In routine practice, patisiran was associated with more favourable effectiveness and tolerability compared to inotersen. Baseline neurological preservation, particularly motor and small-fiber measures, may help identify patients more likely to benefit from treatment. However, these findings should be interpreted with caution due to the limited sample-size and the observational nature of the study.